Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

TOThomas OllilaNGNatalie S. GroverYTYun Kyoung Tiger

Discussion

Loading...

Member takes

Overview

Analysis reveals elevated ferritin linked to increased risks of cytokine release syndrome and neurotoxicity in B-cell lymphoma treatment with bispecific antibodies.

Key Points

  • Identify risk factors for cytokine release syndrome (CRS) and neurotoxicity (NT) during bispecific antibody (BsAb) treatment in B-cell lymphoma patients.
  • Utilized a shared database from 14 institutions on patients with aggressive B-cell lymphoma receiving BsAbs.
  • Collected demographic, treatment, and laboratory data for analysis of CRS and NT occurrences.
  • Applied univariate logistic regression to assess associations between variables and CRS/NT outcomes.
  • 32% of patients experienced any grade CRS during the first cycle; 9% experienced any grade NT.
  • Increased chance of any grade CRS associated with high ferritin and concurrent systemic chemotherapy.
  • Elevated ferritin linked to increased risks for both CRS and NT, suggesting monitoring thresholds for safety.

Cite This Study

Ollila et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e358https://doi.org/10.1182/blood-2025-960
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025 · 1 citations
  2. 2Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas2026
  3. 3Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience2025
  4. 4Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort2025
  5. 5Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper2025 · 3 citations